This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Light Meal on Pharmacokinetic and Pharmacodynamics of Aliskiren in Patients With Mild to Moderate Hypertension

This study has been completed.
Information provided by:
Novartis Identifier:
First received: July 3, 2009
Last updated: February 3, 2010
Last verified: February 2010
The purpose of this study is to determine the effect of a light meal on the pharmacokinetics and pharmacodynamics of aliskiren in patients with mild to moderate hypertension.

Condition Intervention Phase
Hypertension Drug: Aliskiren Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Basic Science
Official Title: A Randomized, Single-blind, Parallel Group, Multiple Oral Dose Study to Evaluate the Effect of a Light Meal on the Pharmacokinetics and Pharmacodynamics of Aliskiren Using Market 300 mg Tablet Formulation in Subjects With Mild to Moderate Hypertension

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Compare PK (AUC & Cmax) and PD, i.e. PRA (Plasma Renin Activity, AUE) of aliskiren when given with and without light meal. [ Time Frame: 28 Days ]

Secondary Outcome Measures:
  • Compare the effect of Plasma Renin Concentration (PRC) and angiotensin II of aliskiren when given with and without light meal [ Time Frame: 28 Days ]
  • Assess safety and tolerability of aliskiren when given with and without light meal [ Time Frame: 28 days ]
  • Evaluate the effect on mean sitting systolic and diastolic blood pressure of aliskiren when given with or without a light meal [ Time Frame: 28 days ]

Enrollment: 124
Study Start Date: June 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Fed Group Drug: Aliskiren
Active Comparator: Fasted group Drug: Aliskiren


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female outpatients, 18 to 65 years of age with mild to moderate hypertension
  • Patients who are eligible and able to participate in the study

Exclusion criteria:

  • Severe hypertension
  • Secondary form of hypertension.
  • Type 1 or type 2 diabetes mellitus
  • Serum potassium out side laboratory reference range
  • Any history of hypertensive encephalopathy or cerebrovascular accident

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00933920

Novartis Investigator Site
Coimbatore, India
Novartis Investigative Site
Hyderabaad, India
Novartis Investigator Site
Hyderabaad, India
Novartis Investigator Site
Mangalore, India
Novartis Investigative Site
New Delhi, India
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: External Affairs, Novartis Pharmaceuticals Identifier: NCT00933920     History of Changes
Other Study ID Numbers: CSPP100A2110
Study First Received: July 3, 2009
Last Updated: February 3, 2010

Keywords provided by Novartis:
renin-angiotensin-aldosterone system,

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases processed this record on August 16, 2017